These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10674266)

  • 1. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
    Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
    Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
    Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
    Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
    Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
    Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
    Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
    Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
    Bouras M; Parvaz P; Berger N; Paulin C; Revol A
    Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
    Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
    Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific amplification by PCR for N-ras mutation in thyroid follicular cartinoma].
    Taniyama M; Kaihara M
    Nihon Rinsho; 1994 Apr; 52(4):1075-80. PubMed ID: 8196166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
    Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
    Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic mutations in thyroid carcinoma.
    Taccaliti A; Boscaro M
    Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
    Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
    Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.